Andrej Vranovský

1.8k total citations
16 papers, 781 citations indexed

About

Andrej Vranovský is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Andrej Vranovský has authored 16 papers receiving a total of 781 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 7 papers in Genetics and 6 papers in Oncology. Recurrent topics in Andrej Vranovský's work include Lymphoma Diagnosis and Treatment (13 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Viral-associated cancers and disorders (5 papers). Andrej Vranovský is often cited by papers focused on Lymphoma Diagnosis and Treatment (13 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Viral-associated cancers and disorders (5 papers). Andrej Vranovský collaborates with scholars based in Slovakia, Russia and Italy. Andrej Vranovský's co-authors include Anton Hagenbeek, Max Wolf, Robert Marcus, Harald Holte, Marinus H. J. van Oers, M. van Glabbeke, Eva Kimby, Richard Klasa, Ivana Teodorović and Mars van’t Veer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal of Internal Medicine.

In The Last Decade

Andrej Vranovský

15 papers receiving 767 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrej Vranovský Slovakia 8 675 450 406 116 113 16 781
W. Hiddemann Germany 2 871 1.3× 627 1.4× 432 1.1× 140 1.2× 156 1.4× 2 969
David Belada Czechia 18 819 1.2× 604 1.3× 327 0.8× 175 1.5× 162 1.4× 167 1.1k
C. Jonas United States 4 509 0.8× 350 0.8× 266 0.7× 87 0.8× 161 1.4× 9 718
Charles Foussard France 12 885 1.3× 601 1.3× 356 0.9× 195 1.7× 85 0.8× 22 1.0k
Richard H. van der Jagt United States 10 740 1.1× 484 1.1× 504 1.2× 116 1.0× 33 0.3× 19 886
Alden A. Moccia Switzerland 15 774 1.1× 475 1.1× 207 0.5× 259 2.2× 117 1.0× 39 871
J. Matthews United Kingdom 13 988 1.5× 664 1.5× 428 1.1× 158 1.4× 73 0.6× 20 1.1k
Santiago Mercadal Spain 12 567 0.8× 403 0.9× 235 0.6× 136 1.2× 39 0.3× 56 710
Alina S. Gerrie Canada 18 800 1.2× 465 1.0× 422 1.0× 260 2.2× 70 0.6× 110 1.1k
F. Morschhauser France 13 693 1.0× 449 1.0× 182 0.4× 166 1.4× 137 1.2× 27 944

Countries citing papers authored by Andrej Vranovský

Since Specialization
Citations

This map shows the geographic impact of Andrej Vranovský's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrej Vranovský with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrej Vranovský more than expected).

Fields of papers citing papers by Andrej Vranovský

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrej Vranovský. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrej Vranovský. The network helps show where Andrej Vranovský may publish in the future.

Co-authorship network of co-authors of Andrej Vranovský

This figure shows the co-authorship network connecting the top 25 collaborators of Andrej Vranovský. A scholar is included among the top collaborators of Andrej Vranovský based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrej Vranovský. Andrej Vranovský is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Chovanec, Michal, Jana Obertová, Patrik Palacka, et al.. (2025). Implementing Indiana regimen salvage high-dose chemotherapy in relapsed germ cell tumors in Slovakia.. Journal of Clinical Oncology. 43(5_suppl). 642–642.
2.
3.
4.
Král, Zdeněk, Heidi Móciková, Jana Marková, et al.. (2019). Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia. Journal of Cancer. 10(21). 5041–5048. 9 indexed citations
5.
Witzens‐Harig, Mathias, Robin Foà, Alice Di Rocco, et al.. (2014). Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study. Annals of Hematology. 93(10). 1717–1724. 23 indexed citations
6.
7.
8.
Oers, Marinus H. J. van, M. van Glabbeke, L. Giurgea, et al.. (2010). Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study. Journal of Clinical Oncology. 28(17). 2853–2858. 225 indexed citations
9.
Wenger, Michael, et al.. (2008). Safety in patients receiving maintenance rituximab for follicular lymphoma: Results from the phase IIIb MAXIMA trial. Journal of Clinical Oncology. 26(15_suppl). 8606–8606. 2 indexed citations
10.
Vranovský, Andrej, et al.. (2008). Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma.. PubMed. 55(2). 107–12. 1 indexed citations
11.
Vranovský, Andrej, et al.. (2008). Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience.. PubMed. 55(5). 428–36. 2 indexed citations
12.
Remková, Anna, et al.. (2007). Acute vasculitis as a first manifestation of hairy cell leukemia. European Journal of Internal Medicine. 18(3). 238–240. 5 indexed citations
13.
Wenger, Michael, Robin Foà, Luca Arcaini, et al.. (2007). The MAXIMA Study: Safety of Rituximab (MabThera®) Maintenance Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma Who Have Responded to Induction Therapy.. Blood. 110(11). 4475–4475. 3 indexed citations
14.
15.
Fermé, Christophe, Marine Diviné, Andrej Vranovský, et al.. (2005). Four ABVD and Involved-Field Radiotherapy in Unfavorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-U Trial.. Blood. 106(11). 813–813. 24 indexed citations
16.
Vranovský, Andrej, et al.. (2002). Coexistence of Philadelphia-positive Chronic Granulocytic Leukemia and Diffuse Large B-cell Lymphoma at Initial Diagnosis. Leukemia & lymphoma. 43(2). 429–431. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by W. Hiddemann Breakdown of academic impact, for papers by David Belada Breakdown of academic impact, for papers by C. Jonas Breakdown of academic impact, for papers by Charles Foussard Breakdown of academic impact, for papers by Richard H. van der Jagt Breakdown of academic impact, for papers by Alden A. Moccia Breakdown of academic impact, for papers by J. Matthews Breakdown of academic impact, for papers by Santiago Mercadal Breakdown of academic impact, for papers by Alina S. Gerrie Breakdown of academic impact, for papers by F. Morschhauser
Rankless by CCL
2026